DeCure for Familial hyperlipidemia

Familial combined hyperlipidemia is genetically heterogeneous, with the first major susceptibility locus mapped to 1q21-23 and the transcription factor USF1 identified as the underlying gene; associated variants are noncoding single nucleotide polymorphisms that affect nuclear protein binding and downstream transcript levels in fat biopsies. Modifier genes influencing the high triglyceride trait include APOC3 and APOA5, the latter being a downstream target of USF1, and linkage evidence exists for additional loci on 16q24 and 20q12-q13.1. A 1999 review of a Finnish isolate confirmed a major gene in a region syntenic to murine chromosome 3, but emphasised that familial combined hyperlipidemia is genetically heterogeneous, with modifier genes such as the apolipoprotein AI-CIII-AIV cluster and LPL identified in several populations.

A 2019 case report describes a 27-day-old neonate born of a third-degree consanguineous marriage with grade III lipemia retinalis secondary to familial combined hyperlipidemia, presenting as hypercholesterolemia or hypertriglyceridemia. A 2024 case report of a 7-year-old boy with type 1 familial hypercholesterolemia due to a mutation in the LDL receptor gene on chromosome 19 notes high risk for cardiovascular disease, cerebrovascular accidents, metabolic syndrome, and premature coronary death. A 2019 study of a four-generation Chinese Han family with hyperlipoproteinemia identified a novel heterozygous deletion of exons 3-16 of the LPA gene using next-generation sequencing and qPCR; clinical manifestations included hyperlipoproteinemia, early-onset hypertension, coronary heart disease, lipoma, cerebral infarction, and sudden death.

One intervention study, from 2002, examined a pharmacist-directed hyperlipidemia management program in 26 chronic hemodialysis patients, using HMG-CoA reductase inhibitors with a dosing algorithm. At baseline, 58% of patients were at target LDL cholesterol of ≤100 mg/dl; at 6 months, 88% achieved target (p = 0.015). Mean LDL decreased from 96 ± 5 to 80 ± 3 mg/dl (p < 0.01), and mean total cholesterol from 170 ± 7 to 151 ± 4 mg/dl (p < 0.01). Fifteen drug therapy adjustments were made, eight adverse drug reactions identified (two requiring discontinuation), and physicians were alerted to eight potential drug-drug interactions. This small, retrospective, single-centre study shows feasibility but provides no data on cardiovascular outcomes.

Reviews from 2005 and 2012 note that despite treatment guidelines, a major part of the population does not achieve recommended LDL targets, especially high-risk groups where most patients are untreated or undertreated; a programme to improve control must address patient compliance, drug efficacy, cost-benefit, and physician quality of care. New international guidelines on familial hypercholesterolaemia and other familial dyslipidaemias were published in 2012, intended to improve quality and cost effectiveness of care. What remains missing is prospective, adequately powered trial evidence linking specific genetic subtypes of familial combined hyperlipidemia to tailored treatment responses, and any outcome data showing that achieving lipid targets in these rare familial forms reduces mortality; current evidence is limited to case reports, genetic linkage studies, and one small retrospective programme.